Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1225–1248 of 2,321 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PET (Positron Emission Tomography) Clear all
Completed No phase listed Observational Accepts healthy volunteers

Enriching Clinical Trials Requiring Amyloid Positivity With Practice Effects

NCT03466736
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
[18F]flutemetamol PET scan
Diagnostic Test
Lead sponsor
University of Utah
Other
Eligibility
65 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 25, 2026, 2:12 PM EDT
Recruiting Phase 1 Interventional

Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors

NCT05687136
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Peposertib, Positron Emission Tomography, Tuvusertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Bethesda, Maryland • Boston, Massachusetts • Mineola, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 25, 2026, 2:12 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours

NCT05397171
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
Interventions
AZD8853, Zirconium-89 crefmirlimab berdoxam
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Flortaucipir F 18

NCT02278367
View directory record Official record
Conditions
Alzheimer's Disease, Traumatic Brain Injury, Depression
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
5
States / cities
Phoenix, Arizona • New Haven, Connecticut • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 25, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT01028209
View directory record Official record
Conditions
Alzheimer Disease, Parkinson Disease, Multiple Sclerosis
Interventions
[18F] PBR06
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 25, 2026, 2:12 PM EDT
Recruiting Phase 3 Interventional

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

NCT07166406
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8
Interventions
Atezolizumab, Bevacizumab, Biospecimen Collection, Computed Tomography, Durvalumab, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Questionnaire Administration, Stereotactic Body Radiation Therapy, Tremelimumab
Biological · Procedure · Other + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2034
U.S. locations
138
States / cities
Berkeley, California • Cameron Park, California • Fremont, California + 108 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 25, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers

NCT03903549
View directory record Official record
Conditions
Parkinson Disease
Interventions
[18F]P17-059
Drug
Lead sponsor
Five Eleven Pharma, Inc.
Industry
Eligibility
45 Years to 90 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 25, 2026, 2:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Assessment of [18F]MNI-1054 as a Marker for LSD1

NCT03695926
View directory record Official record
Conditions
Healthy Volunteers (HV)
Interventions
[18F]MNI-1054
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 50 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 23, 2019 · Synced Oct 25, 2026, 2:12 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study for the Safety and Evaluation of Two 4R Tau Ligands as Potential PET Radioligands for Imaging Tau Protein in the Brain

NCT07348276
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP), Healthy Participants
Interventions
[18F]ABBV-964i, [18F]ABBV-965i, Lead Candidate
Drug
Lead sponsor
Invicro
Other
Eligibility
18 Years to 80 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 25, 2026, 2:12 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access [Ga-68] PSMA-11 PET Imaging

NCT04800068
View directory record Official record
Conditions
Prostate Cancer
Interventions
[Ga-68] PSMA-11 PET/CT, [Ga-68] PSMA-11 PET/MR
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 21, 2022 · Synced Oct 25, 2026, 2:12 PM EDT
Terminated Phase 3 Interventional

Phase III Trial of PET/CT vs. CTSurveilance for Head and Neck Cancer

NCT02655068
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
PET/CT, Computed Tomography (CT)
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 25, 2026, 2:12 PM EDT
Completed No phase listed Observational

Metabolic Abnormalities in Children With Epilepsy

NCT00001325
View directory record Official record
Conditions
Generalized Epilepsy, Infantile Spasms, Metabolic Disease, Partial Epilepsy, Seizures
Interventions
18 FDG
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 25, 2026, 2:12 PM EDT
Completed Early Phase 1 Interventional

Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective

NCT01873248
View directory record Official record
Conditions
Neuroendocrine Tumors
Interventions
68Ga-DOTATATE
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 25, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma

NCT03262389
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Fludeoxyglucose PET CT, Sodium Acetate C11 PET CT, Fludeoxyglucose PET MRI, Sodium Acetate C11 PET MRI
Drug
Lead sponsor
Michael C Roarke, MD
Other
Eligibility
20 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 25, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Results available

Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer

NCT00966992
View directory record Official record
Conditions
Uterine Cervical Neoplasms
Interventions
Zoledronic acid
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Oct 25, 2026, 2:12 PM EDT
Not listed Phase 3 Interventional

18F-Fluciclovine PET Imaging for Detecting High Grade Glioma Recurrence After Radiochemotherapy

NCT05479136
View directory record Official record
Conditions
Grade III or Grade IV Glioma
Interventions
PET imaging with 18F fluciclovine
Drug
Lead sponsor
Nicole Hill
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Oct 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT06242834
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma
Interventions
Biospecimen Collection, Computed Tomography, Echocardiography, Pembrolizumab, Positron Emission Tomography, Tazemetostat
Procedure · Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Chicago, Illinois • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 25, 2026, 2:12 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

PET Imaging in Parkinson Disease Dementia

NCT01052350
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 25, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

NCT04279561
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 25, 2026, 2:12 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

R21 Roche: 3-Way Tau Tracers in AD

NCT05464368
View directory record Official record
Conditions
Alzheimer Disease
Interventions
[18F]RO-948, 18F-MK6240, 18F-GTP1
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 25, 2026, 2:12 PM EDT
Terminated Phase 1 Interventional

Multimodal Imaging Outcome Measures for ALS (Image ALS)

NCT04490096
View directory record Official record
Conditions
ALS
Interventions
[11C]-PBR28
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 12, 2022 · Synced Oct 25, 2026, 2:12 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

PET Imaging CCR2 in Lung Inflammation

NCT03492762
View directory record Official record
Conditions
Lung Inflammation
Interventions
Cu-DOTA-ECL1i
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 2:12 PM EDT
Terminated Early Phase 1 Interventional

MRI and PET to Assess Pembrolizumab Response

NCT02591654
View directory record Official record
Conditions
Malignant Melanoma, Metastatic
Interventions
Pembrolizumab, FLT PET
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 30, 2022 · Synced Oct 25, 2026, 2:12 PM EDT
Recruiting Phase 2 Interventional

Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy

NCT06510361
View directory record Official record
Conditions
Lymphoma, Follicular Lymphoma, Lymphoma,Non-Hodgkin, Lymphoma, Non-Hodgkin's, Adult
Interventions
Epcoritamab
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Stanford, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 25, 2026, 2:12 PM EDT